Predict the future with Zilver PTX

Choose Zilver PTX and its unmatched body of evidence to provide your patients with predictable¹, safe², and sustained 5-year results²

The challenge of treating PAD is that each individual patient presents unique circumstances and lesion characteristics that must be considered prior to treatment. We’ve used our extensive data to create a one-of-a-kind prediction model that allows you to input patient and lesion characteristics quickly and easily with predicted results calculated in real-time. This prediction model can be used on any platform, including on a tablet or phone, allowing you to discuss predicted outcomes in an easy, convenient manner with your patients. 

CardioVascular and Interventional Radiology published a peer-reviewed article written by Dake, et al. on our prediction model for patients treated with Zilver PTX. The model includes data generated from more than 2200 patients in five global studies, including the Zilver PTX randomized controlled trial. 

The first-of-its kind tool for a drug-based endovascular device in the SFA allows you to input 15 different patient and lesion characteristics to predict your own patient’s probability of freedom from TLR at 5 years when treated with Zilver PTX. 

The only SFA dataset that provides you with a fully transparent, patient-level probability of SFA reintervention.